SIBN: SI-BONE Company Sales Revenue

SI-BONE, Inc. (SIBN) leadership in sacroiliac joint therapy and the trust of orthopedic surgeons are creating powerful market momentum. The company's sales volatility confirms this trend, where the current metric equals 0.22. Growth is based on the patent protection of the iFuse system, while the strategy relies on expanding insurance reimbursements and training physicians in new minimally invasive intervention methods.

Revenue and Sales Volume: SI-BONE (SIBN) for 07/04/2022 - 11/14/2026

Comprehensive metric breakdowns and analytics for SI-BONE Medical (SIBN)

- current price and projected stock value:

Share Price SI-BONE|SIBN - Consensus Target

- market capitalization information:

Market Value SI-BONE Corp|SIBN - Total Company Value

- balance sheet net asset value indicators:

Accounting Value per Share SI-BONE|SIBN - Book Capitalization|Market-to-Book Ratio si-bone.com|SIBN - Company Total Assets

- company liabilities and liquidity data:

- company profitability and valuation multiples indicators:

SIBN - Net Income|Expected Net Income SI-BONE, Inc.|SIBN - P/E Multiple|Projected Price to Earnings Ratio SI-BONE Inc|SIBN - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Multiple SI-BONE Medical|SIBN - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) SI-BONE|SIBN - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months si-bone.com|SIBN - Earnings per share growth in current year|Net earnings per share change forecast for next year SI-BONE, Inc.

- company sales and revenue statistics:

SIBN - Company Revenue|Company Future Sales Volume SI-BONE, Inc.|SIBN - P/S Multiple|Market Cap to Future Revenue Ratio SI-BONE Corp

Summary company analysis:SIBN SI-BONE, Inc.

This indicator measures daily aggregate sales revenue, neutralizing random market fluctuations to identify the true revenue trend. The metric allows for an assessment of the commercial plan's effectiveness through continuous sales dynamics. By analyzing the aggregated sales of SI-BONE, Inc. (SIBN), an investor can see the impact of minimally invasive technique adoption rates and insurance coverage on the cash flow of SI-BONE, Inc. (SIBN). Steady growth of the line confirms successful surgeon training, which minimizes capital risks.

Key competitors